As breakthrough drugs offer critical hope to patients, lawmakers should focus on shoring up the social safety net ...

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9 ...

India’s regulators are tightening oversight as obesity drug makers race to shape demand in the country’s emerging weight-loss ...

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Merck narrows 2026 outlook, but analysts see revision as less compelling Investors focus on pipeline and efforts to reduce reliance on Keytruda Merck booked $3.62-per-share charge for Cidara buyout ...

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Merck (MRK) is scheduled to report first-quarter earnings on April 30, during market hours, with analysts expecting a strong performance from Keytruda and Winrevair. Seeking Alpha analyst ALLKA ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...

The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...

Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...